ALK and neoplasm: In a phase III trial (KEYNOTE-024) comparing pembrolizumab with platinum-doublet chemotherapy in chemo-naïve patients whose tumor was positive for PD-L1 ≥ 50%, patients who had EGFR or ALK alterations were excluded.